Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated
Benzinga Newsdesk 11 hours ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancerKAT6A degradation was active in both ESR1-mutant and wild-type cell modelsDegraders
- Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancer
- KAT6A degradation was active in both ESR1-mutant and wild-type cell models
- Degraders were well-tolerated in all groups
